secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036391
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance
--------------------------------------------------------------------------------

- Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
- Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.
- Company had failed to meet bid price requirement by March 25, 2024 compliance date.
- GLTO continues trading under same symbol; reverse stock split is under consideration.
- If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/0000950170-24-036391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/glto-20240322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer